RecruitingRecruiting
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
NCT03503331 · University of Alabama at Birmingham
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer \[C-11\]PiB in participants in the UAB-ADC cohort. The amount and distribution of \[C-11\]PiB in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study. Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with \[C-11\]PiB-PET, and cognitive status will be the primary outcome of this imaging study. As a secondary aim, the investigators will assess the ability of the early flow frames from \[C-11\]PiB-PET and brain volumetric measurements with MRI to serve as a marker of neuronal injury and to predict cognitive status in conjunction with the amyloid-PET results.
Eligibility criteria
Inclusion Criteria:
\- 1. Enrollment in the UAB-ADC study under a separate IRB-approved research protocol (IRB-300000169).
2\. Negative urine or serum B-hCG test within 2 days of \[C-11\]PiB administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.
Exclusion Criteria:
1. Meets any exclusion criteria for the UAB-ADC study (IRB-300000169).
2. Inability or contraindication for undergoing MRI and/or PET imaging
3. Inability to participate in the imaging studies due to severity of dementia
Study design
Enrollment target: 160 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2018-04-20
Estimated completion: 2028-10
Last updated: 2025-12-11
Interventions
Drug: [C-11]PiB-PET/MRI
Primary outcomes
- • Measurement of pathological beta-amyloid in the brain (5 years)
Sponsor
University of Alabama at Birmingham · other
With: National Institute on Aging (NIA)
Contacts & investigators
ContactChinara Dosse · contact · cdosse@uabmc.edu · (205) 975-7017
ContactEvan Hudson · contact · evanhudson@uabmc.edu · 205-934-6499
InvestigatorJonathan McConathy, MD · principal_investigator, University of Alabama at Birmingham
All locations (1)
University of Alabama at Birmingham Medical CenterRecruiting
Birmingham, Alabama, United States